CryoPort, Inc. (NASDAQ:CYRX) had its price objective raised by Needham & Company LLC from $8.50 to $10.00 in a research note issued to investors on Wednesday morning. They currently have a buy rating on the stock.

Other equities analysts also recently issued research reports about the company. Janney Montgomery Scott set a $8.00 price objective on CryoPort and gave the company a buy rating in a research report on Wednesday, July 26th. ValuEngine upgraded CryoPort from a sell rating to a hold rating in a research report on Thursday, May 11th. Finally, Cowen and Company lifted their price objective on CryoPort from $5.50 to $7.50 and gave the company an outperform rating in a research report on Wednesday, August 9th.

CryoPort (NASDAQ:CYRX) opened at 6.85 on Wednesday. The stock has a 50 day moving average of $6.53 and a 200-day moving average of $4.15. The firm’s market capitalization is $169.02 million. CryoPort has a one year low of $1.80 and a one year high of $8.23.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. CryoPort had a negative return on equity of 67.75% and a negative net margin of 102.89%. The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $2.84 million. On average, equities analysts predict that CryoPort will post ($0.72) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “CryoPort, Inc. (CYRX) Given New $10.00 Price Target at Needham & Company LLC” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/cryoport-inc-cyrx-given-new-10-00-price-target-at-needham-company-llc/1533432.html.

A number of institutional investors have recently modified their holdings of the stock. Northern Trust Corp increased its position in shares of CryoPort by 105.0% in the second quarter. Northern Trust Corp now owns 22,179 shares of the company’s stock valued at $109,000 after buying an additional 11,358 shares during the last quarter. BerganKDV Wealth Management LLC increased its position in shares of CryoPort by 157.5% in the second quarter. BerganKDV Wealth Management LLC now owns 25,750 shares of the company’s stock valued at $127,000 after buying an additional 15,750 shares during the last quarter. EAM Investors LLC acquired a new position in shares of CryoPort during the second quarter valued at about $552,000. D.A. Davidson & CO. increased its position in shares of CryoPort by 16.6% in the second quarter. D.A. Davidson & CO. now owns 137,000 shares of the company’s stock valued at $674,000 after buying an additional 19,500 shares during the last quarter. Finally, Taylor Wealth Management Partners acquired a new position in shares of CryoPort during the second quarter valued at about $1,851,000. Hedge funds and other institutional investors own 12.05% of the company’s stock.

About CryoPort

Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.

Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.